|
**Overview**: HIV-1 RNA CD3 CD4 Panel**Introduction**: The HIV-1 RNA CD3 CD4 Panel is a diagnostic tool designed to monitor HIV-1 and immune status using whole blood samples. In India, ~2.4 million people live with HIV, with CD4 count and viral load essential for ART initiation (CD4 <350 or symptomatic) and monitoring suppression (<50 copies/mL). High morbidity from under-monitoring in rural/low-SES patients, limited labs, delayed ART switch leading to opportunistic infections or AIDS progression. Per immunology/microbiology practices aligned with NACO and WHO guidelines, the test combines PCR for HIV-1 RNA quantitative and flow cytometry for CD3/CD4 counts over 1-2 days with high accuracy, valuable for staging and treatment response. This diagnostic falls under viral load monitoring and targets HIV-positive patients on ART or pre-ART, addressing accurate detection to guide therapy adjustment. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise immune/virologic assessment and reducing AIDS mortality. Its whole blood-based approach ensures reliable integrated monitoring.**Other Names**: HIV 1 RNA Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/immunology/hematology, compliant with 2025 standards.**Historical Milestone**: HIV RNA/CD4 standard; in India, scaled under NACO.**Purpose**: The test assesses 6 parameters including HIV-1 RNA quantitative to guide monitoring, assess viral suppression/immune status, inform ART.**Test Parameters**: 1. HIV-1 RNA Quantitative, 2. CD3 Count, 3. CD4 Count, 4. CD4 Percentage, 5. Total Lymphocytes, 6. Viral Load.**Pretest Condition**: No fasting required; patients should have confirmed HIV.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell/RNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable for flow; RNA stable frozen.**Medical History**: Patients should provide details on ART status, CD4 history, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of poor monitoring including progression, benefits of assessment, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low CD4 can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High viral load/low CD4 indicates poor control, necessitating specialist input.**Specialist Consultation**: HIV specialists should be consulted for management.**Additional Supporting Tests**: Resistance testing for confirmation.**Test Limitations**: Requires fresh sample for flow; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, HIV Studies India 2023. |
